Washington — The U.S. Supreme Court issued a decision on Friday that sharply limits the ability of plaintiffs to pursue Roundup‑related cancer claims in federal court, directing most of the more than 100,000 lawsuits to state courts instead. The ruling, hailed by Bayer AG as a “significant victory,” curtails the scope of the ongoing federal multidistrict litigation (MDL) that had been used to coordinate claims against the herbicide’s active ingredient, glyphosate.
What happened
In a per curiam opinion, the Court held that the federal courts lack jurisdiction over the majority of the Roundup cases, effectively narrowing the MDL that had been overseen by the U.S. District Court for the District of Minnesota. The decision does not dismiss any individual claims; rather, it bars plaintiffs from filing new suits in federal court and requires many existing cases to be heard in the state courts where the alleged injuries occurred. Bayer AG, the German parent of Roundup, declined to comment publicly on the order.
Why it matters
The Supreme Court’s move reshapes the legal battlefield for one of the most extensive product‑liability campaigns in U.S. history. By fragmenting the litigation across hundreds of state jurisdictions, the ruling could dilute the collective bargaining power of plaintiffs and make a nationwide settlement—such as the $10.9 billion agreement Bayer reached in 2020—more difficult to achieve. Legal analysts note that the decision may also reduce the immediate financial pressure on Bayer, which has already set aside billions of dollars to cover potential liabilities. At the same time, the shift places greater emphasis on state courts’ interpretation of scientific evidence linking glyphosate to cancer, potentially leading to divergent outcomes.
Background and context
Roundup, a glyphosate‑based herbicide, has been the subject of litigation since the early 2010s. Plaintiffs—primarily individuals diagnosed with non‑Hodgkin lymphoma—have alleged that exposure to glyphosate caused their disease. By 2026, more than 100,000 plaintiffs had filed claims in both state and federal courts, seeking compensation for medical costs, lost wages, and punitive damages. In 2015, the International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans,” a finding that spurred a wave of lawsuits. Bayer, which acquired Monsanto—the original developer of Roundup—in 2018, has consistently defended the safety of glyphosate, citing U.S. Environmental Protection Agency (EPA) assessments that found no unreasonable risk when used according to label instructions.
The federal MDL, created in 2022, was intended to streamline pre‑trial proceedings, consolidate discovery, and promote consistency across cases. Over the past four years, the MDL produced a series of rulings on issues such as the admissibility of expert testimony and the applicability of federal product‑liability law. The Supreme Court’s latest decision reverses that trajectory, signaling a judicial preference for state‑level adjudication of product‑safety claims.
Competing claims and uncertainty
The ruling does not resolve the core scientific dispute over glyphosate’s carcinogenicity. Plaintiffs’ attorneys continue to argue that epidemiological studies and internal Monsanto documents demonstrate a causal link between glyphosate exposure and non‑Hodgkin lymphoma. Bayer and its allies counter that the totality of scientific evidence, including EPA and European Food Safety Authority (EFSA) reviews, does not support such a connection.
State courts may apply different standards for expert testimony, causation, and damages, creating uncertainty about the ultimate liability Bayer could face. Some legal scholars warn that the fragmented approach could prolong the litigation, increase costs for both parties, and result in inconsistent verdicts. Others contend that state courts are better positioned to consider local regulatory contexts and that the decision respects the principle of federalism by preventing a single federal forum from becoming a de facto “court of public opinion.”
What to watch next
The immediate next step is for state courts to receive the transferred cases and set procedural schedules. Watch for motions to dismiss filed by Bayer in key jurisdictions such as California, Texas, and New York, where prior rulings have varied. The outcomes of those motions will indicate how many cases will survive to trial.
In parallel, the litigation is likely to influence ongoing regulatory reviews. The EPA is expected to issue a final rule on glyphosate’s re‑evaluation later this year; any adverse state‑court rulings could pressure the agency to tighten safety standards. Additionally, the decision may affect settlement negotiations. Plaintiffs’ groups have signaled that a unified federal settlement is now “unlikely,” suggesting they may pursue a coordinated strategy through state‑level coalitions.
Finally, the case could set precedent for other mass‑tort product‑liability actions. Observers will monitor whether the Supreme Court’s jurisdictional reasoning is cited in future attempts to consolidate large numbers of claims—such as those involving opioid manufacturers or asbestos exposure—under federal MDLs.
Conclusion
The Supreme Court’s ruling marks a pivotal shift in the Roundup litigation, moving the bulk of the dispute from a single federal forum to a patchwork of state courts. While the decision does not address the scientific controversy over glyphosate, it reshapes the legal landscape, potentially limiting the scale of any future settlement and increasing the variability of outcomes. As state courts begin to hear the cases, the next months will reveal whether Bayer can contain its exposure or whether plaintiffs will achieve localized victories that could cumulatively pressure the company and regulators.
Sources
Al Jazeera, “US Supreme Court scales back Roundup cancer lawsuits in victory for company,” June 25 2026, https://www.aljazeera.com/economy/2026/6/25/us-supreme-court-scales-back-roundup-cancer-lawsuits-in-victory-for-company?traffic_source=rss
Story synopsis gathered from: Al Jazeera News — source
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
